By Associate Professor Michael Falster

Conference Presentations

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M; de Oliveira Costa J, 2023, 'Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues', presented at Australian Diabetes Congress 2023

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023

Shawon MSR; Falster M; Hsu B; Yu J; Ooi S-Y; Jorm L, 2022, 'Temporal trends in rates and risk-adjusted outcomes for coronary revascularization in New South Wales (2003-2017)', presented at UNSW Annual Cardiovascular Symposium 2022, UNSW Sydney, 05 April 2022 - 05 April 2022

Back to profile page